Decaf vs Caffeinated Coffee

Table of Contents

1. Why Decaf Exists — the Medical Use Cases
2. Decaf Is Not Zero Caffeine
3. Swiss Water Process
4. Supercritical CO2 Process
5. Ethyl Acetate ("Natural" Decaf)
6. Methylene Chloride Process
7. CGA and Flavor Retention Across the Four Processes
8. Benefits That Survive Decaffeination
9. Benefits That Do Not Survive Decaffeination
10. Decaf in Pregnancy
11. Decaf for Sleep Disorders and Anxiety
12. Decaf for Hypertension, Arrhythmia, and Slow Metabolizers
13. The Half-Caf Strategy
14. Key Research Papers
15. Connections
16. Featured Videos

Why Decaf Exists — the Medical Use Cases

Decaf has a poor reputation among coffee enthusiasts and is often viewed as a flavor-compromised substitute for the "real thing." That framing misses the substantial population for whom decaf serves a medical purpose. The major use cases:

• Pregnancy — ACOG and most national obstetric societies recommend limiting caffeine to under 200 mg/day during pregnancy due to associations with low birth weight, miscarriage, and pregnancy loss in higher-intake observational studies. A pregnant woman who drinks 2-3 cups of coffee daily exceeds this limit; cutting back or shifting to decaf brings intake under it. Approximately 4 million pregnancies occur annually in the United States; the decaf market for pregnancy alone is large.
• Panic disorder and severe anxiety — caffeine reliably triggers panic attacks in panic-disorder patients at doses (300-450 mg) that affect controls minimally. Panic-disorder patients are typically advised to limit or eliminate caffeine. Decaf preserves the social and ritual aspects of coffee without the panic-provoking pharmacology. See Anxiety for more.
• Atrial fibrillation and other arrhythmias — the relationship between coffee and arrhythmia is complex (most observational studies find no significant association in light-to-moderate drinkers, and some find protection), but for patients with known atrial fibrillation who notice palpitations after caffeine, decaf removes the caffeine while keeping the drink. The European Society of Cardiology guidance is generally permissive about coffee in atrial fibrillation (AF) patients, but individual sensitivity varies.
• Severe insomnia — patients with established insomnia who cannot tolerate even morning caffeine due to prolonged half-life or extreme sensitivity benefit from decaf throughout the day or from switching to decaf after noon.
• Slow CYP1A2 metabolizers — the ~55% of the population with the AC or CC genotype at rs762551 metabolize caffeine slowly enough that a single morning cup can produce 8-12 hours of measurable effect. For people whose phenotype matches (described as "coffee makes me wired" or "I can't handle even half a cup"), decaf preserves the polyphenol and ritual benefits without the prolonged caffeine load. See the Cognitive Performance page CYP1A2 section.
• Gastroesophageal reflux disease (GERD) — both caffeinated and decaffeinated coffee can trigger reflux symptoms (coffee acidity and lower esophageal sphincter relaxation are partly caffeine-independent), but caffeinated coffee is worse in most patients. Switching to decaf is a common first change for mild reflux, and people commonly report cold brew and dark-roast decaf as the best tolerated.
• Adolescents — the American Academy of Pediatrics advises against routine caffeine consumption in adolescents under 18, recommending no more than 100 mg/day for children 12-18. Teen coffee drinkers who want the experience and polyphenol intake without the caffeine load can use decaf.
• Elderly patients with anxiety or sleep disorders — caffeine sensitivity tends to increase with age due to slower metabolism and increased autonomic reactivity. Many elderly patients tolerate decaf well even when they cannot tolerate caffeinated.

The combined population with one or more of these medical reasons easily reaches 15-35% of adults at any given time, more if the broad "caffeine sensitivity" category is included. The decaf market exists for substantive reasons.

Back to Table of Contents

Decaf Is Not Zero Caffeine

The best-known numeric limits for decaf are European Union rules: no more than 0.1% caffeine by dry weight for roast and ground decaf, and 0.3% for instant. These limits translate to:

• A 240 mL cup of brewed decaf typically contains 2-15 mg of caffeine.
• The same cup of regular coffee contains 80-200 mg.
• So decaf delivers roughly 2-10% of the caffeine of regular coffee, depending on the decaf brand and the regular comparator.

For most adults, 2-15 mg of caffeine is pharmacologically insignificant — the threshold for measurable cognitive effects is around 30-50 mg. For pregnant women with a 200 mg/day cap, decaf is well within the limit even at 5 cups a day. For very caffeine-sensitive patients (severe panic disorder, severe insomnia, certain arrhythmias), the residual caffeine in decaf can still produce noticeable effects in a subset of patients — the most sensitive people often move to caffeine-free herbal infusions (chamomile, peppermint, rooibos).

The residual caffeine content varies meaningfully across brands and processes. Independent testing by a consumer-testing group and others has found:

• A large coffee chain's decaf (CO2 process): 12-25 mg per 16 oz serving
• A major supermarket brand's decaf (methylene chloride): 8-15 mg per 8 oz cup
• Swiss Water Process decafs (various brands): 1-7 mg per 8 oz cup, generally the lowest residual
• Some "swiss water" decafs from grocery store private labels: 5-15 mg, suggesting actual process varies
• Instant decaf: typically 3-8 mg per 8 oz reconstituted

In this testing, Swiss Water Process decafs carried the lowest residual caffeine, and some packages state the residual caffeine on the label.

Back to Table of Contents

Swiss Water Process

Developed in Switzerland in the 1930s and commercialized at scale by a water-process decaffeination company in British Columbia, this is the only major decaffeination process that uses no chemical solvents at any step.

Process overview:

1. A batch of green coffee beans is soaked in hot water to dissolve caffeine plus most of the other water-soluble compounds (CGAs, sugars, soluble proteins, etc.)
2. The resulting liquid (called "Green Coffee Extract," GCE) is passed through activated carbon filters with pore size selected to retain caffeine while letting CGAs and flavor compounds pass through.
3. The de-caffeinated GCE, now saturated with CGAs and flavor compounds but stripped of caffeine, is used to soak a fresh batch of green beans. Because the GCE is already saturated with all the non-caffeine soluble compounds, the only thing the new beans lose to the water is their caffeine.
4. The new beans, now decaffeinated, are dried and shipped. The GCE is filtered through activated carbon again and reused on the next batch.

Result: 99.9% caffeine removal, with most CGAs, sugars, and flavor compounds retained because they were already in solution equilibrium and did not need to leave the bean.

Advantages:

• No chemical solvent residue. Suitable for organic and chemical-free designations.
• Best CGA retention among the four major processes (typically 80-90% of original CGA content).
• Good flavor retention.
• Low residual caffeine, with the company claiming 99.9% removal (typically 1-5 mg residual per cup).

Disadvantages:

• More expensive than solvent-based methods, both in capital equipment and process cost. This is reflected in the higher retail price of Swiss Water decafs.
• Process is slower (typically 8-10 hours per batch).

Swiss Water Process is the decaf method with no solvent at any step. Packages made this way name it explicitly ("Swiss Water Process" or "SWP") — the term "water process" without "Swiss" may refer to other water-based processes with different specifications.

Back to Table of Contents

Supercritical CO2 Process

Developed in Germany in the 1970s by Kurt Zosel. Uses CO2 at supercritical conditions (above 31°C and 74 bars pressure, where the gas-liquid distinction disappears) as a selective solvent for caffeine.

Process overview:

1. Green beans are softened with steam to open pore structure.
2. The beans are placed in a high-pressure vessel and supercritical CO2 is circulated through them. At supercritical conditions, CO2 selectively dissolves caffeine while leaving most flavor compounds (which are non-polar or polar with hydrogen-bonding character) largely intact.
3. The caffeine-laden CO2 is decompressed and the caffeine precipitates out. The CO2 is reused.
4. The decaffeinated beans are dried and shipped. The recovered caffeine is sold to the pharmaceutical and soft-drink industries.

Result: ~97% caffeine removal. Better CGA and flavor retention than chemical solvent methods (because CO2 is selective for caffeine vs the larger polar molecules).

Advantages:

• No chemical solvent residue (CO2 itself is benign and present in trace amounts in the final bean).
• Good CGA retention (typically 70-85% of original).
• Reasonable flavor retention.
• Highly scalable; suited to large industrial operations. Much large-scale commodity decaf production, including some major supermarket brands and a large coffee chain's decaf, uses CO2.

Disadvantages:

• Higher capital cost (high-pressure equipment).
• Slightly less selective than Swiss Water for caffeine vs other compounds, so flavor retention is marginally lower than SWP.

CO2 process is the "mass market chemical-free" option, widely available at moderate price points. It is the dominant process for a large coffee chain's decaf and many other major brands.

Back to Table of Contents

Ethyl Acetate ("Natural" Decaf)

Uses ethyl acetate as the caffeine solvent. Ethyl acetate is a small organic molecule (CH3-COO-CH2-CH3) that occurs naturally in many fruits, particularly bananas and apples (responsible for some of their characteristic aroma). When marketed as "natural decaf," the ethyl acetate is sometimes derived from natural sources (sugarcane fermentation in Colombia is a common source), although the chemical itself is identical whether from natural or synthetic origin.

Process overview:

1. Green beans are softened with steam.
2. The beans are soaked in or circulated with ethyl acetate, which selectively extracts caffeine.
3. The caffeine-laden ethyl acetate is removed and the beans are steamed to remove residual ethyl acetate.
4. The decaffeinated beans are dried and shipped.

Result: ~97% caffeine removal. Moderate flavor retention.

Advantages:

• Lower capital cost than CO2 process.
• The "natural" designation when sugarcane-derived ethyl acetate is used is a marketing advantage in some markets, particularly Latin American and specialty-coffee markets.
• Process is well established and reliable.

Disadvantages:

• Some loss of the more volatile flavor compounds compared to Swiss Water or CO2.
• Residual ethyl acetate is detectable in trace amounts in some samples. U.S. Food and Drug Administration rules (21 CFR 173.228) allow ethyl acetate as a decaffeination solvent for coffee and tea under good manufacturing practice, without a set ppm residue limit. Although the residue is harmless and ethyl acetate is generally recognized as safe-classified, the "solvent" perception affects some consumers.
• CGA retention typically 65-80%, slightly lower than CO2 or SWP.

Ethyl acetate decaf is common in Colombian specialty decaf offerings and in some premium organic decaf brands. The "sugar cane decaf" label often indicates ethyl acetate process from sugarcane-derived solvent.

Back to Table of Contents

Methylene Chloride Process

Solvent decaffeination dates to the early 1900s: Ludwig Roselius, founder of an early German decaf brand, and two co-inventors patented a process (US patent 897,840, filed 1906, issued 1908) that extracted caffeine from steamed green beans with benzene or a benzene-alcohol mixture. Today's solvent process uses dichloromethane (methylene chloride, CH2Cl2) as the caffeine solvent.

Process overview is similar to ethyl acetate, with methylene chloride substituted as the solvent. The methylene chloride has higher selectivity for caffeine than ethyl acetate, generally producing better flavor retention. Residual methylene chloride in the beans is volatile and is largely evaporated during roasting (boiling point 39.6°C, vs roasting temperature of 196-235°C).

Result: ~97% caffeine removal. Best flavor retention among solvent-based methods, often considered indistinguishable from regular coffee by sensory panels at the higher quality tier.

Advantages:

• Lower cost than Swiss Water or CO2.
• Excellent flavor retention.
• Highly selective for caffeine vs other compounds, so good CGA retention (70-85%).
• Well-established process used by most low-cost commodity decaf brands.

Controversies and safety:

• Methylene chloride is on the International Agency for Research on Cancer (IARC) Group 2A list (probably carcinogenic to humans) based on animal carcinogenicity studies.
• U.S. Food and Drug Administration limits residual methylene chloride in decaf coffee to 10 ppm. Independent testing of commercial decaf typically finds residuals well below this limit (often less than 1 ppm and frequently undetectable).
• The EU EFSA reviewed methylene chloride decaf in 2023 and concluded that consumer exposure is well below health-based guidance values.
• On 11 January 2024 the U.S. Food and Drug Administration announced in the Federal Register that it had filed a food additive petition from the Environmental Defense Fund and other groups, asking it to remove four solvents — benzene, ethylene dichloride, methylene chloride and trichloroethylene — from its food additive rules. On 28 May 2026 the FDA reopened the comment period to collect updated data from the two years since. No ban has been issued and there is no effective date; the 10 ppm residue limit for decaf coffee (21 CFR 173.255) still stands.
• Major brands have been transitioning away from methylene chloride preemptively. One major supermarket brand moved to ethyl acetate in 2023, and other major brands are reformulating.

The practical assessment: the actual health risk from methylene chloride residue in commercially produced decaf coffee is small, based on the trace residual amounts and the volatility-driven loss during roasting. The advocacy and regulatory pressure is driven more by precautionary principle (because chemical-free alternatives exist, why use a probable carcinogen at all) than by demonstrated harm in the coffee context. Swiss Water, CO2 and ethyl acetate decafs, named as such on the label, involve no methylene chloride.

Back to Table of Contents

CGA and Flavor Retention Across the Four Processes

Approximate ranking of the four processes for CGA retention, residual solvent concerns, and flavor preservation:

• Swiss Water Process — best CGA retention (80-90%), no solvent concerns, very good flavor. Most expensive at retail.
• Supercritical CO2 — very good CGA retention (70-85%), no solvent concerns, good flavor. Mid-to-high retail price.
• Methylene chloride — good CGA retention (70-85%), regulatory uncertainty / advocacy concern despite small actual residue, excellent flavor. Lowest retail price.
• Ethyl acetate — moderate CGA retention (65-80%), no major solvent concerns, moderate flavor retention. Mid-range retail price.

Ranked on CGA retention and solvent concerns, the order is Swiss Water > CO2 > ethyl acetate > methylene chloride. Ranked on flavor, the order shifts to Swiss Water = methylene chloride > CO2 > ethyl acetate. For the "cheap decaf for office break room" use case, methylene chloride still dominates although that is changing rapidly.

Across all four processes, decaf delivers 65-90% of the CGA content of equivalent regular coffee at equivalent roast level. The non-caffeine polyphenol benefits are substantially preserved — this is the main health case made for decaf.

Back to Table of Contents

Benefits That Survive Decaffeination

The following coffee benefits are preserved in decaf, based on the published evidence:

• Type 2 diabetes risk reduction — both caffeinated and decaffeinated coffee show inverse association with T2D incidence in pooled analyses (Salazar-Martinez 2004, van Dam 2006). A 2014 dose-response meta-analysis by Ding and colleagues pooled 28 cohort studies with 1,109,272 people and 45,335 cases of diabetes: each extra daily cup was tied to 9% lower diabetes risk for regular coffee (relative risk 0.91) and 6% lower for decaf (0.94). The difference between the two was not statistically significant (P = 0.17). Chlorogenic acid's effect on after-meal blood sugar is one proposed explanation; these cohort studies did not test the mechanism.
• Hepatic protection (non-alcoholic fatty liver disease (NAFLD), fibrosis, hepatocellular carcinoma) — meta-analyses find similar protective effects for caffeinated and decaffeinated coffee, suggesting the active mechanism is largely non-caffeine. See the Remedies/Coffee/Benefits liver-related pages.
• Type 2 diabetes-associated cardiovascular risk reduction — partially preserved in decaf.
• Anti-inflammatory effects measured by C-reactive protein (CRP) and interleukin-6 (IL-6) — partially preserved.
• Gut microbiome support (Bifidobacterium enrichment, butyrate production) — preserved in decaf, as melanoidins and CGAs are the active mechanisms.
• Mild blood pressure benefit (with chronic CGA exposure) — preserved and arguably more visible in decaf since the caffeine pressor effect that obscures it in regular coffee is removed.
• Polyphenol-mediated effects on endothelial function — preserved.
• Niacin and trigonelline-derived metabolite delivery — preserved.
• Modest cerebral blood flow improvement — partially preserved (CGAs are mild cerebral vasodilators).
• Iron-binding effect on non-heme iron absorption — fully preserved (melanoidin-mediated). This is mostly a negative for iron-deficient drinkers and only relevant for separating coffee from iron-rich meals.

The summary: most CGA- and melanoidin-mediated benefits are preserved. The decaf drinker gets approximately 80% of the polyphenol-driven benefit of the regular-coffee drinker, with essentially none of the caffeine load.

Back to Table of Contents

Benefits That Do Not Survive Decaffeination

The following benefits depend on caffeine and are largely lost in decaf:

• Cognitive alertness and vigilance improvement — almost entirely caffeine-mediated. Decaf produces a small placebo and CGA-cerebral-blood-flow effect but nothing approaching the caffeine effect.
• Reaction time improvement — caffeine-dependent.
• Ergogenic / exercise performance benefits — almost entirely caffeine-mediated. Decaf is not an ergogenic aid.
• Mood elevation — partially caffeine-mediated (the adenosine antagonism contributes); some social/ritual mood effect of warm beverage preserved.
• Parkinson's disease risk reduction — mostly caffeine-mediated. Decaf shows much weaker or absent protection in most cohort studies, although a few find some residual effect (possibly EHT-mediated).
• Headache and migraine abortive effect — caffeine-mediated via cerebral vasoconstriction. Decaf cannot substitute for the caffeine in combination headache tablets containing caffeine.
• Acute blood pressure pressor effect — caffeine-mediated. This is generally a benefit of decaf in hypertensive patients (the pressor effect is removed), although it means decaf does not produce the temporary cognitive lift that the pressor effect partially mediates.
• Diuretic effect — caffeine-mediated. Decaf is essentially non-diuretic.
• Suppression of appetite — modestly caffeine-mediated. Most appetite-suppression benefit is lost in decaf.
• Adenosine-mediated late-day "second wind" — caffeine-specific.

The summary: cognitive and performance benefits require caffeine and are largely lost in decaf. Long-term metabolic and hepatic benefits largely survive. The choice between caffeinated and decaf is therefore aligned with what the drinker wants from the cup — alertness and performance vs polyphenol intake and ritual.

Back to Table of Contents

Decaf in Pregnancy

ACOG and most national obstetric societies recommend limiting caffeine to under 200 mg/day during pregnancy. The CARE study (CARE Study Group, BMJ 2008) followed 2,635 low-risk pregnant women at two UK hospitals and measured fetal growth restriction (a baby growing too slowly in the womb). Compared with under 100 mg/day, intake of 100-199 mg/day had an odds ratio of 1.2 (not statistically significant), 200-299 mg/day 1.5, and over 300 mg/day 1.4. Risk rose with dose (test for trend P<0.001), the link held throughout pregnancy, and it was stronger in women who cleared caffeine faster.

What these figures mean for pregnant women who drink coffee:

1. Two 8-oz cups of regular drip coffee approach or exceed the 200 mg threshold. Staying under 200 mg/day on regular coffee works out to about 1-2 cups/day.
2. Decaf is well within the limit even at 4-6 cups/day. At typical intakes, decaf keeps caffeine far below the 200 mg figure.
3. Caffeine half-life is dramatically prolonged in pregnancy, particularly the third trimester (10-12 hours vs 5 hours non-pregnant), due to reduced CYP1A2 activity and increased plasma protein binding. The same morning cup that clears by evening in a non-pregnant woman remains circulating overnight in a third-trimester pregnant woman. Decaf largely removes this issue because it carries so little caffeine.
4. Decaf preserves the polyphenol benefits (relevant for gestational diabetes risk reduction, where the CGA effect on glucose absorption is potentially helpful). The 2-15 mg residual caffeine in decaf is well below the conservative pregnancy threshold.
5. Swiss Water and CO2 process decafs involve no methylene chloride. There is no specific evidence that the trace methylene chloride residue in conventional decaf is harmful in pregnancy; some people choose solvent-free decaf on precautionary grounds.

In sum: Swiss Water Process or CO2-process decaf throughout pregnancy, with at most a single morning regular cup, keeps total caffeine under the 200 mg/day figure. The polyphenol intake is preserved; the caffeine concern is essentially eliminated.

Back to Table of Contents

Decaf for Sleep Disorders and Anxiety

Insomnia, anxiety, and panic disorder patients are often advised to limit or eliminate caffeine. How decaf is commonly used in each situation:

• Mild insomnia: a common approach is decaf after noon, with morning regular coffee usually tolerated. The 10-12 hour residual caffeine from morning intake is the most common iatrogenic insomnia driver and is often missed by patients who think their morning cup "does not bother me at night."
• Severe insomnia or unresponsive to other interventions: a common approach is full caffeine elimination (decaf throughout the day, or no coffee at all) for 2-4 weeks to see the effect on sleep. Most patients see meaningful improvement; some find decaf alone is sufficient and a small morning regular cup can be reintroduced.
• Anxiety disorder without panic: a 2-4 week decaf trial is a common approach; many patients find substantial improvement in baseline anxiety. If decaf does not relieve the anxiety, the caffeine was probably not the dominant driver.
• Panic disorder: full caffeine elimination is typically recommended. Even decaf occasionally triggers symptoms in highly sensitive panic-disorder patients, though usually 2-5 mg of residual caffeine is well below the threshold for panic provocation.
• Restless legs syndrome: caffeine commonly aggravates symptoms. Decaf or no coffee removes this trigger.
• Bruxism (tooth grinding): caffeine can worsen bruxism in sleep. Decaf after noon removes the evening caffeine.

See our Insomnia page and Anxiety page for more comprehensive management. The decaf switch is one of the highest-leverage, lowest-cost interventions for both conditions and is often skipped in clinical practice.

Back to Table of Contents

Decaf for Hypertension, Arrhythmia, and Slow Metabolizers

The cardiovascular benefit-vs-harm of regular coffee depends substantially on CYP1A2 genotype (see Cognitive Performance page for the gene-environment interaction story). For slow metabolizers and people with specific cardiovascular conditions, decaf removes the caffeine-related effects:

• Stage 1 hypertension: not an absolute contraindication to regular coffee, but the acute pressor effect of 5-10 mmHg is potentially clinically relevant in patients on the borderline of treatment threshold. Switching to decaf removes the pressor effect while preserving the CGA-mediated mild antihypertensive effect — the net is typically a 3-7 mmHg systolic reduction in patients who switch.
• Stage 2 hypertension or refractory hypertension: decaf removes the pressor effect entirely. Patients on multiple antihypertensives can usually tolerate one morning regular cup, and decaf throughout the rest of the day reduces the cumulative pressor load.
• Slow CYP1A2 metabolizers (rs762551 AC/CC): epidemiologically associated with increased MI risk at higher coffee intake. Decaf removes that caffeine load for slow metabolizers who otherwise drink more than ~2 cups/day of regular coffee.
• Atrial fibrillation: data are mixed; most studies find no significant association between coffee intake and atrial fibrillation incidence or recurrence. Atrial fibrillation patients who notice coffee triggering symptoms often switch to decaf.
• SVT, frequent PVCs/PACs: caffeine commonly triggers symptoms in sensitive patients, and decaf removes this trigger.
• Long QT syndrome and recurrent syncope: caffeine is generally permitted but the autonomic effects can complicate. Decaf is often advised in patients with recurrent presentations.

For cardiovascular patients, the decaf decision is usually about removing the acute caffeine pressor and sympathetic activation effects while preserving the long-term polyphenol-driven cardiometabolic benefits. The result is a beverage choice that is essentially all upside and no downside for most cardiovascular patients.

Back to Table of Contents

The Half-Caf Strategy

For drinkers who want some caffeine effect but less total exposure, the "half-caf" approach blends regular and decaf in roughly 50/50 ratio — either by pre-mixed whole bean (sold by many roasters), by alternating cups, or by literally adding decaf to a partly-poured cup of regular.

Practical math: a half-caf cup delivers 40-100 mg of caffeine (half the 80-200 mg of regular) plus most of the polyphenol content of a regular cup (slightly more than half, since both regular and decaf contain CGAs). For a person who wants the alertness lift without exceeding 200 mg/day, three half-caf cups deliver 120-300 mg of caffeine spread across the day — manageable for most adults.

The half-caf approach is particularly useful for:

• Tapering off regular coffee toward decaf over weeks (shifting the ratio gradually toward decaf reduces withdrawal headache)
• Pregnant women in early pregnancy who want some caffeine effect while staying under 200 mg/day
• Slow CYP1A2 metabolizers who want more than just morning regular without sleep disruption
• People who notice anxiety, palpitations, or tremor from full regular intake but find decaf unsatisfying
• Late-afternoon cups when full caffeine would disrupt sleep

Most major specialty roasters offer half-caf blends; many coffee shops will prepare half-caf espresso drinks on request. The price is typically the same as regular (the decaf component is more expensive but the blending evens it out).

Back to Table of Contents

Key Research Papers

1. Salazar-Martinez E, Willett WC, Ascherio A, Manson JE, Leitzmann MF, Stampfer MJ, Hu FB (2004). Coffee consumption and risk for type 2 diabetes mellitus. Annals of Internal Medicine 140(1):1-8. — PubMed PMID: 14706966
2. van Dam RM, Hu FB (2005). Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA. — PubMed PMID: 15998896
3. Saab S et al. (2014). Impact of coffee on liver diseases: a systematic review. Liver International. — PubMed PMID: 24102757
4. CARE Study Group (2008). Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study. BMJ 337:a2332. — PubMed PMID: 18981029
5. Riksen NP, Smits P, Rongen GA (2011). The cardiovascular effects of methylxanthines. Handbook of Experimental Pharmacology (200):413-37. — PubMed PMID: 20859806
6. Klatsky AL, Hasan AS, Armstrong MA, Udaltsova N, Morton C (2011). Coffee, caffeine, and risk of hospitalization for arrhythmias. Permanente Journal 15(3):19-25. — PubMed PMID: 22058665
7. Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, Willett WC (2001). Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Annals of Neurology 50(1):56-63. — PubMed PMID: 11456310
8. Bhupathiraju SN et al. (2014). Changes in coffee intake and subsequent risk of type 2 diabetes: three large cohorts. Diabetologia. — PubMed PMID: 24771089
9. Jee SH et al. (1999). The effect of chronic coffee drinking on blood pressure: a meta-analysis. Hypertension. — PubMed PMID: 10024321
10. Chu YF et al. (2009). Roasted coffees high in lipophilic antioxidants and chlorogenic acid lactones are more neuroprotective. Journal of Agricultural and Food Chemistry. — PubMed PMID: 19772322
11. Ding M, Bhupathiraju SN, Chen M, van Dam RM, Hu FB (2014). Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis. Diabetes Care 37(2):569-86. — PubMed PMID: 24459154
12. U.S. Food and Drug Administration (2024). Filing of Food Additive Petition From Environmental Defense Fund, et al.; Request To Amend the Food Additive Regulations To Remove the Solvents Benzene, Ethylene Dichloride, Methylene Chloride, and Trichloroethylene. Federal Register, 11 January 2024. — Federal Register 2024-00411
13. U.S. Food and Drug Administration (2026). Food Additive Petition From Environmental Defense Fund, et al.; Request To Amend the Food Additive Regulations To Remove the Solvents Benzene, Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period. Federal Register, 28 May 2026. — Federal Register 2026-10615
14. Meyer JF Jr, Roselius L, Wimmer KH. Preparation of coffee. US patent 897,840, filed 4 May 1906, issued 1 September 1908. — US897840A

PubMed Topic Searches

1. PubMed: Decaf coffee T2D
2. PubMed: Decaf coffee liver
3. PubMed: Coffee in pregnancy
4. PubMed: Decaffeination process comparison
5. PubMed: Methylene chloride safety

Back to Table of Contents

Connections

• All Food
• Caffeine, Adenosine & Why Coffee Stops Working — interactive animation
• Coffee Benefits Hub (Food Science)
• Polyphenols and Chlorogenic Acid
• Cognitive Performance
• Bean Variety and Roast
• Coffee (Food Hub)
• Coffee (Remedies Benefits Hub)
• Coffee Cardiovascular & Mortality
• Hypertension
• Atrial Fibrillation
• Anxiety
• Insomnia
• Type 2 Diabetes
• Parkinson's Disease
• Gastroesophageal Reflux Disease
• History
• Nutrients

Back to Table of Contents

Featured Videos